BeOne Medicines (ONC) Interest Coverage Ratio (2015 - 2026)
BeOne Medicines (ONC) reported Interest Coverage Ratio of 7.6 for Q1 2026, up 379.25% year-over-year from 1.59 in Q1 2025, and up 379.25% on a QoQ basis from 1.59 in Q1 2025.
BeOne Medicines (ONC) has 4 years of Interest Coverage Ratio data on file, last reported at 7.6 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 379.25% year-over-year to 7.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.86 (up 149.38% YoY) and the FY2025 annual result came in at 7.68, up 129.47% from the prior year.
- Interest Coverage Ratio climbed to 7.6 in Q1 2026 per ONC's latest filing, from 1.59 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 7.6 in Q1 2026 and bottomed at 1.59 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 49.84 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 11.50 |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 3.88 |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 7.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.60 |
| Mar 31, 2025 | 1.59 |
| Sep 30, 2016 | -122.63 |
| Jun 30, 2016 | -174.67 |
| Mar 31, 2016 | -99.68 |
| Sep 30, 2015 | -46.64 |
| Jun 30, 2015 | -24.05 |
| Mar 31, 2015 | -36.75 |